ProShares UltraShort Nasdaq Biotechnology
NASDAQ · us_market
No AI summary generated yet for this ticker.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
First quarter results point to sharpened sector divergence, separating AI-driven winners from those facing structural and geopolitical headwinds.
US growth stocks underperformed in early 2026 amid AI disruption fears and an unresolved conflict in the Middle East.
Active equity investors Carrie King and Erin Xie address key questions about healthcare stocks. Read more here.
Longevity, the length of human life, is the subject of growing scientific and commercial interest. Click here to read more.
The Trump administrationâs recent cuts at the FDA have put the agencyâs executive capacity under strain, which may lead to medicine shortages and less innovation.
While AI remains the dominant theme in corporate earnings, Morningstar Research's David Sekera says investors should keep in mind that not all tech stocks are created equal. Read more here.
Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic.
Australian shares are experiencing a slight dip as the country navigates potential fuel rationing and global geopolitical tensions, leading investors to adopt a cautious stance. Despite these challenges, penny stocks remain an intriguing area of focus for those seeking opportunities beyond the mainstream indices. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer significant value and growth potential when backed by strong financials.
AI applications in healthcare have emerged across four key areas: prediction, diagnosis, treatment, and system efficiency. Read more here.
Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Read more here.
After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Read more here.
US launch of Operation Epic Fury against Iran in late February triggered the closure of the Strait of Hormuz, spiking energy prices and driving pressure on both equities and bonds.
The U.S. military campaign against the Iranian theocracy has roiled financial markets. As a result of the incursion, oil prices are surging and are up 90%+ since the beginning of the year.
As the Australian market navigates a challenging landscape marked by geopolitical tensions and natural disruptions, investors are keenly observing the impact on local indices, with a notable downturn expected at the open. In such uncertain times, dividend stocks often attract attention for their potential to provide steady income streams despite market volatility.
After years of technology dominance, market leadership appears to be shifting; will it last? Click here to read more.
Mid-cap stocks can help investors diversify beyond big tech. Mid-caps in the healthcare space are benefitting from AI developments. Read more here.
Learn how LABD delivers -3x daily biotech exposure, why itâs down 99.98% since inception, and when it fits short-term trades.